IMNN - Imunon Short-Term Debt to Capital

Historical price action demonstrates the debt-to-equity ratio of Imunon, Inc. (IMNN), which currently stands at 0.52. Imunon, Inc. (IMNN) is developing breakthrough ovarian cancer treatments via the Placcine system. Despite maintaining a sufficient cash reserve, business success depends on the test results of plasmid platforms. Meanwhile, financial stability remains susceptible to regulatory pauses and the necessity of issuing new shares to cover research costs.

For the biotechnology company Imunon, Inc. (IMNN), which faces high operating expenses and a lack of revenue, liquidity control is critical. By analyzing the short-term debt-to-equity ratio on GURU.Markets, an investor assesses the proportion of liabilities maturing within one year relative to net assets. A decrease in this ratio minimizes the risk of bankruptcy in the event of failed clinical trials, confirming the issuer's financial stability.